Purchase this article with an account.
Rosa Dolz-Marco, Roberto Gallego-Pinazo, M Dolores Pinazo-Duran, Sheila Pons-Vazquez, Manuel Diaz-Llopis; Preclinical Safety Of Intravitreal Docosahexaenoic Acid In A Rabbit Model. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5363.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the retinal toxicity of intravitreal administration of the purified fatty acid docosahexaenoic (DHA) in rabbit eyes.
Sixteen New Zealand albino rabbits were selected. Six concentrations of DHA (Brudy Laboratories, Barcelona, Spain) were prepared: 10, 5 and 2.5 µg/1 µL; and 50, 25, and 5 µg/50 µL. A volume of 0.05 ml of each concentration was injected intravitreally in the right eye of 2 rabbits. As a control, 0.05 ml of saline solution was injected into in the right eye of 4 animals. Retinal safety of intravitreal DHA was assesed by electroretinography (ERG) -changes between before and 1 week after the injection-; and by histologic examination of the retinal samples obtained after sacrificing the rabbits.
We evidenced a severe intraocular inflammation in eyes treated with 10 µg/1 µL, 5 µg/1 µL and 2’5 µg/1 µL DHA concentrations. The ERG studies -amplitude and time of A and B waves- did not show significant difference (p< 0,01) between control and DHA-injected eyes. The histologic examination did not evidence any retinal abnormality in the rabbits injected with different concentrations of DHA.
DHA may be a safe intravitreal drug in the rabbit model up to 50 µg/50 µL. Further studies are warranted to evaluate the safety and efficacy in human.
This PDF is available to Subscribers Only